NAMSA announced that it has entered into a definitive agreement to acquire the U.S. medical device testing operations of WuXi AppTec.
Under the agreement, NAMSA will acquire WuXi AppTec facilities in Minnesota and Georgia.
The MedTech industry faces more stringent regulatory and clinical evidence requirements, which can delay development, increase costs, and slow market entry. NAMSA's strategic outsourcing and comprehensive in-house services help MedTech innovators mitigate risk, shorten time to market and enhance stakeholder value.
Both companies will work closely to ensure a smooth transition for employees and customers.
NAMSA is an ARCHIMED company; acquired by the healthcare-focused global private equity firm in 2020. The acquisition of WuXi AppTec’s U.S. Medical Device Testing Operations is the 9th acquisition by NAMSA since becoming an ARCHIMED company.
